Aktienanalyse zu Surrozen Inc (SRZN)SRZNSurrozen Inc

Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Surrozen Inc (SRZN) appears to be a good buy right now due to its significant revenue growth of 410.2% year-over-year in Q1 2026, alongside a strong cash position of $106.9 million, which supports its operational funding. Despite recent losses, the company's gross margin remains at 100%, indicating efficient cost management in its operations. However, the main risk is the negative earnings per share (EPS) of -$11.65, which highlights ongoing financial challenges that investors should monitor closely.